Market Summary
USD177.72+1.04
Market Closed0.59%
ZTS Alerts
ZTS Stock Price
ZTS RSI Chart
ZTS Valuation
ZTS Price/Sales (Trailing)
ZTS Profitability
ZTS Fundamentals
ZTS Revenue
ZTS Earnings
Price Action
52 Week Range
124.15194.99
(Low)(High)
Last 7 days
-1.1%
Last 30 days
-2.8%
Last 90 days
4.1%
Trailing 12 Months
18.7%
ZTS Financial Health
ZTS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ZTS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-18 | Lagano Roxanne | sold | -165,752 | 179 | -923 | executive vice president |
2023-09-15 | Chen Heidi C. | sold | -1,784,390 | 180 | -9,905 | executive vice president |
2023-09-01 | Lagano Roxanne | sold | -178,111 | 192 | -923 | executive vice president |
2023-08-22 | PECK KRISTIN C | sold | -2,339,560 | 179 | -13,000 | chief executive officer |
2023-08-22 | PECK KRISTIN C | acquired | 589,585 | 45.3527 | 13,000 | chief executive officer |
2023-08-09 | Polzer Robert J | acquired | 169,811 | 144 | 1,179 | executive vice president |
2023-08-09 | Polzer Robert J | sold | -223,939 | 189 | -1,179 | executive vice president |
2023-05-23 | PECK KRISTIN C | sold | -2,295,330 | 176 | -13,000 | chief executive officer |
2023-05-23 | PECK KRISTIN C | acquired | 543,790 | 41.83 | 13,000 | chief executive officer |
2023-05-19 | Norden Gregory | gifted | - | - | -2,659 | - |
Which funds bought or sold ZTS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Halpern Financial, Inc. | new | - | 3,272 | 3,272 | -% |
2023-09-21 | Baystate Wealth Management LLC | added | 0.23 | 2,643 | 73,976 | 0.01% |
2023-09-20 | BARCLAYS PLC | added | 106 | 79,311,000 | 149,114,000 | 0.09% |
2023-09-18 | CAPE ANN SAVINGS BANK | added | 2.67 | 46,634 | 795,725 | 0.53% |
2023-09-14 | IMS Capital Management | added | 7.08 | 44,153 | 453,429 | 0.25% |
2023-09-13 | CGC Financial Services, LLC | new | - | 2,928 | 2,928 | -% |
2023-09-12 | Prosperity Financial Group, Inc. | reduced | -1.63 | 14,235 | 812,315 | 0.72% |
2023-09-12 | Farther Finance Advisors, LLC | added | 3.75 | 6,530 | 95,243 | 0.02% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | 6.00 | 172 | -% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 5,166 | 5,166 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
ZTS Alerts
Schedule 13G FIlings of Zoetis
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 7.91% | 36,850,763 | SC 13G/A | |
| Feb 06, 2023 | blackrock inc. | 8.6% | 40,082,444 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 8.5% | 40,315,810 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.79% | 37,023,889 | SC 13G/A | |
| Feb 01, 2021 | blackrock inc. | 8.6% | 40,720,915 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 7.85% | 37,400,083 | SC 13G/A | |
| Feb 06, 2020 | blackrock inc. | 8.7% | 41,563,670 | SC 13G/A |
Recent SEC filings of Zoetis
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 22, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 22, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Zoetis)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 496.9B | 29.5B | -0.25% | 77.82% | 76.47 | 16.84 | 1.53% | 14.16% |
JNJ | 416.4B | 97.8B | -3.60% | -2.56% | 31.9 | 4.26 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -3.97% | 23.63% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 186.2B | 77.9B | -9.35% | -24.54% | 8.67 | 2.39 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -4.70% | -15.70% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.99% | 679.20% | -74.1 | 4.1K | -86.94% | 71.24% |
PRGO | 4.4B | 4.6B | -14.16% | -15.49% | -64.33 | 0.94 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.7B | 627.1M | -7.75% | -5.51% | -1.16 | 2.69 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -9.02% | -13.66% | 35.75 | 2.44 | 0.62% | -24.59% |
INVA | 851.8M | 244.3M | -1.80% | 10.68% | 4.32 | 3.49 | -39.50% | -4.99% |
CRON | 830.8M | 109.5M | 28.99% | -23.78% | -5.79 | 7.59 | -2.66% | -32.13% |
CGC | 519.0M | 453.3M | 141.77% | -66.80% | -0.42 | 1.14 | -16.04% | 55.90% |
ACRS | 464.2M | 31.2M | -4.93% | -49.81% | -4.41 | 14.9 | 407.54% | -26.47% |
OCUL | 252.8M | 54.6M | -17.99% | -39.70% | -2.79 | 4.63 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Zoetis News
Returns for ZTS
Cumulative Returns on ZTS
19.8%
10-Year Cumulative Returns
20.1%
7-Year Cumulative Returns
15.1%
5-Year Cumulative Returns
3.9%
3-Year Cumulative Returns
Risks for ZTS
What is the probability of a big loss on ZTS?
49.2%
Probability that Zoetis stock will be more than 20% underwater in next one year
36.5%
Probability that Zoetis stock will be more than 30% underwater in next one year.
4.2%
Probability that Zoetis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ZTS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Zoetis was unfortunately bought at previous high price.
Drawdowns
Financials for Zoetis
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.6% | 8,222 | 8,094 | 8,080 | 8,007 | 7,995 | 7,891 | 7,776 | 7,616 | 7,412 | 7,012 | 6,675 | 6,542 | 6,340 | 6,339 | 6,260 | 6,150 | 6,046 | 5,914 | 5,825 | 5,721 | 5,588 |
| S&GA Expenses | 1.3% | 2,076 | 2,049 | 2,009 | 2,088 | 2,091 | 2,057 | 2,001 | 1,928 | 1,848 | 1,746 | 1,726 | 1,678 | 1,645 | 1,658 | 1,638 | 1,586 | 1,562 | 1,515 | 1,484 | 1,425 | 1,386 |
| EBITDA | -100.0% | - | 3,328 | 3,342 | 3,246 | 3,236 | 3,201 | 3,160 | 3,070 | 3,015 | 2,861 | 2,668 | 2,683 | 2,604 | 2,561 | 2,436 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.41* | 0.41* | 0.41* | - | 0.41* | 0.41* | 0.40* | 0.41* | 0.41* | 0.40* | 0.41* | 0.41* | 0.40* | 0.39* | 0.39* | - | - | - | - | - |
| Interest Expenses | 2.2% | 236 | 231 | 221 | 213 | 216 | 220 | 224 | 228 | 234 | 235 | 231 | 229 | 223 | 220 | 223 | 226 | 224 | 215 | 206 | 197 | 186 |
| Earnings Before Taxes | 7.7% | 2,828 | 2,626 | 2,656 | 2,570 | 2,562 | 2,528 | 2,488 | 2,402 | 2,340 | 2,186 | 1,996 | 2,013 | 1,944 | 1,917 | 1,801 | 1,782 | 1,672 | 1,654 | 1,690 | 1,702 | 1,697 |
| EBT Margin | -100.0% | - | 0.32* | 0.33* | 0.32* | - | 0.32* | 0.32* | 0.32* | 0.32* | 0.31* | 0.30* | 0.31* | 0.31* | 0.30* | 0.29* | 0.29* | - | - | - | - | - |
| Net Income | 6.9% | 2,213 | 2,071 | 2,114 | 2,067 | 2,090 | 2,073 | 2,037 | 1,982 | 1,909 | 1,774 | 1,638 | 1,663 | 1,617 | 1,611 | 1,500 | 1,461 | 1,375 | 1,388 | 1,428 | 1,164 | 1,115 |
| Net Income Margin | -100.0% | - | 0.26* | 0.26* | 0.26* | - | 0.26* | 0.26* | 0.26* | 0.26* | 0.25* | 0.25* | 0.25* | 0.26* | 0.25* | 0.24* | 0.24* | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 1,458 | 1,326 | 1,267 | 1,429 | 1,607 | 1,736 | 1,791 | 1,702 | 1,682 | 1,673 | 1,523 | 1,456 | 1,323 | 1,335 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.0% | 13,749 | 13,754 | 14,925 | 13,674 | 13,770 | 13,860 | 13,900 | 13,705 | 14,069 | 13,796 | 13,609 | 13,725 | 13,069 | 11,528 | 11,545 | 11,272 | 10,986 | 10,883 | 10,800 | 10,459 | 8,603 |
| Current Assets | -1.4% | 6,183 | 6,269 | 7,506 | 6,551 | 6,651 | 6,837 | 6,930 | 6,682 | 7,048 | 6,794 | 6,611 | 6,757 | 6,285 | 4,772 | 4,748 | 4,618 | 4,484 | 4,379 | 4,399 | 4,076 | 4,239 |
| Cash Equivalents | -18.6% | 1,717 | 2,109 | 3,581 | 2,507 | 2,652 | 3,135 | 3,485 | 3,274 | 3,658 | 3,602 | 3,604 | 3,654 | 3,353 | 1,951 | 1,934 | 1,815 | 1,755 | 1,728 | 1,602 | 1,286 | 1,558 |
| Inventory | 5.4% | 2,701 | 2,563 | 2,345 | 2,303 | 2,205 | 2,057 | 1,923 | 1,875 | 1,802 | 1,700 | 1,628 | 1,626 | 1,584 | 1,481 | 1,410 | 1,439 | 1,404 | 1,361 | 1,391 | 1,441 | 1,420 |
| Net PPE | 3.4% | 3,011 | 2,913 | 2,753 | 2,623 | 2,559 | 2,487 | 2,422 | 2,338 | 2,286 | 2,227 | 2,202 | 2,099 | 2,011 | 1,977 | 1,940 | 1,813 | 1,739 | 1,683 | 1,658 | 1,556 | 1,470 |
| Goodwill | -0.9% | 2,714 | 2,738 | 2,746 | 2,692 | 2,720 | 2,685 | 2,682 | 2,703 | 2,718 | 2,707 | 2,694 | 2,690 | 2,629 | 2,583 | 2,592 | 2,550 | 2,505 | 2,522 | 2,519 | 2,537 | 1,514 |
| Liabilities | -1.5% | 9,128 | 9,263 | 10,522 | 9,012 | 9,190 | 9,202 | 9,356 | 9,024 | 9,717 | 9,704 | 9,836 | 10,118 | 10,082 | 8,775 | 8,837 | 8,594 | 8,575 | 8,566 | 8,592 | 8,341 | 6,621 |
| Current Liabilities | -7.6% | 1,769 | 1,915 | 3,167 | 2,880 | 3,051 | 3,034 | 1,797 | 1,471 | 2,091 | 2,066 | 2,170 | 2,400 | 1,811 | 1,721 | 1,806 | 1,052 | 1,075 | 1,082 | 1,223 | 1,003 | 967 |
| Short Term Borrowings | -33.3% | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | - | - | - | 4.00 | 4.00 | 4.00 | 1.00 | 1.00 | - | - | - | - | - | 9.00 | - | - |
| LT Debt, Current | - | - | - | 1,350 | 1,350 | 1,350 | 1,350 | - | - | 600 | 600 | 600 | 1,100 | 500 | - | 500 | - | - | - | - | - | - |
| LT Debt, Non Current | -0.1% | 6,555 | 6,559 | 6,552 | 5,210 | 5,221 | 5,228 | 6,592 | 6,592 | 6,592 | 6,587 | 6,595 | 6,595 | 7,194 | 5,963 | 5,947 | 6,447 | 6,446 | 6,444 | 6,443 | 6,441 | 4,955 |
| Shareholder's Equity | 3.0% | 4,625 | 4,491 | 4,405 | 4,663 | 4,580 | 4,658 | 4,544 | 4,681 | 4,352 | 4,092 | 3,773 | 3,607 | 2,987 | 2,753 | 2,708 | 2,678 | 2,411 | 2,317 | 2,185 | 2,118 | 1,982 |
| Retained Earnings | 5.5% | 9,543 | 9,045 | 8,668 | 8,533 | 8,004 | 7,628 | 7,186 | 7,044 | 6,492 | 6,099 | 5,659 | 5,526 | 5,048 | 4,764 | 4,427 | 4,217 | 3,788 | 3,495 | 3,270 | 3,067 | 2,722 |
| Additional Paid-In Capital | 1.8% | 1,098 | 1,079 | 1,088 | 1,073 | 1,059 | 1,046 | 1,068 | 1,056 | 1,044 | 1,030 | 1,065 | 1,040 | 1,030 | 1,017 | 1,044 | 1,031 | 1,019 | 1,008 | 1,026 | 1,010 | 1,001 |
| Accumulated Depreciation | 3.1% | 2,447 | 2,374 | 2,297 | 2,232 | 2,193 | 2,141 | 2,072 | 2,113 | 2,064 | 2,012 | 1,952 | 1,894 | 1,818 | 1,769 | 1,737 | 1,725 | 1,685 | 1,642 | 1,599 | 1,559 | 1,522 |
| Shares Outstanding | -0.4% | 461 | 462 | 464 | 466 | 470 | 472 | 473 | 474 | 475 | 476 | 475 | 476 | 475 | 476 | 476 | 478 | 479 | 480 | 480 | 482 | 484 |
| Minority Interest | -33.3% | -4.00 | -3.00 | -2.00 | -1.00 | - | - | 1.00 | 2.00 | 2.00 | 3.00 | 4.00 | 5.00 | 5.00 | - | - | - | - | - | - | - | 12.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -7.1% | 1,999 | 2,152 | 1,912 | 1,850 | 1,977 | 2,122 | 2,213 | 2,252 | 2,161 | 2,118 | 2,126 | 1,990 | 1,934 | 1,814 | 1,795 | 1,797 | 1,841 | 1,790 | 1,790 | 1,814 | 1,703 |
| Share Based Compensation | 3.6% | 57.00 | 55.00 | 62.00 | 60.00 | 60.00 | 61.00 | 58.00 | 57.00 | 56.00 | 56.00 | 59.00 | 62.00 | 64.00 | 65.00 | 67.00 | 68.00 | 52.00 | 37.00 | 53.00 | 24.00 | 27.00 |
| Cashflow From Investing | 12.5% | -858 | -981 | -883 | -587 | -577 | -513 | -458 | -493 | -553 | -578 | -572 | -608 | -643 | -538 | -504 | -365 | -2,220 | -2,237 | -2,259 | -2,239 | -303 |
| Cashflow From Financing | 5.4% | -2,045 | -2,161 | -904 | -1,998 | -2,388 | -2,068 | -1,862 | -2,145 | -1,319 | 112 | 123 | 470 | 331 | -1,036 | -951 | -898 | 597 | 552 | 533 | -237 | -544 |
| Buy Backs | -8.4% | 1,389 | 1,516 | 1,594 | 1,387 | 1,208 | 923 | 743 | 545 | 347 | 181 | 250 | 426 | 576 | 726 | 626 | 600 | 593 | 658 | 698 | 673 | 655 |
ZTS Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |||||
| Income Statement [Abstract] | ||||||||
| Revenue | $ 2,180 | $ 2,052 | $ 4,180 | $ 4,038 | ||||
| Costs and expenses: | ||||||||
| Cost of sales | 607 | 625 | 1,195 | 1,194 | ||||
| Selling, general and administrative expenses | 556 | 529 | 1,061 | 994 | ||||
| Research and development expenses | 146 | 135 | 288 | 257 | ||||
| Amortization of intangible assets | 37 | 37 | 74 | 78 | ||||
| Restructuring charges and certain acquisition-related costs | 8 | 1 | 29 | 3 | ||||
| Interest expense, net of capitalized interest | 58 | 53 | 121 | 106 | ||||
| Other (income)/deductions—net | (104) | 2 | (157) | 9 | ||||
| Income before provision for taxes on income | 872 | 670 | 1,569 | [1] | 1,397 | [1] | ||
| Provision for taxes on income | 202 | 141 | 348 | 274 | ||||
| Net income before allocation to noncontrolling interests | 670 | 529 | 1,221 | 1,123 | ||||
| Less: Net loss attributable to noncontrolling interests | (1) | 0 | (2) | (1) | ||||
| Net income attributable to Zoetis Inc. | $ 671 | $ 529 | $ 1,223 | $ 1,124 | ||||
| Earnings per share attributable to Zoetis Inc. stockholders: | ||||||||
| Basic (in dollars per share) | $ 1.45 | $ 1.13 | $ 2.64 | $ 2.39 | ||||
| Diluted (in dollars per share) | $ 1.45 | $ 1.12 | $ 2.64 | $ 2.38 | ||||
| Weighted-average common shares outstanding: | ||||||||
| Basic (in shares) | 461.9 | 470.0 | 462.7 | 471.1 | ||||
| Diluted (in shares) | 462.9 | 471.5 | 463.8 | 472.8 | ||||
| Dividends paid per common share (in dollars per share) | $ 0.375 | $ 0.325 | $ 0.750 | $ 0.650 | ||||
| ||||||||
ZTS Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 | ||
|---|---|---|---|---|
| Assets | ||||
| Cash and cash equivalents | [1] | $ 1,717 | $ 3,581 | |
| Accounts receivable, less allowance for doubtful accounts of $20 in 2023 and $19 in 2022 | 1,322 | 1,215 | ||
| Inventories | 2,701 | 2,345 | ||
| Other current assets | 443 | 365 | ||
| Total current assets | 6,183 | 7,506 | ||
| Property, plant and equipment, less accumulated depreciation of $2,447 in 2023 and $2,297 in 2022 | 3,011 | 2,753 | ||
| Operating lease right of use assets | 224 | 220 | ||
| Goodwill | 2,714 | 2,746 | ||
| Identifiable intangible assets, less accumulated amortization | 1,252 | 1,380 | ||
| Noncurrent deferred tax assets | 192 | 173 | ||
| Other noncurrent assets | 173 | 147 | ||
| Total assets | 13,749 | 14,925 | ||
| Liabilities and Equity | ||||
| Short-term borrowings | 2 | 2 | ||
| Current portion of long-term debt | 0 | 1,350 | ||
| Accounts payable | 464 | 405 | ||
| Dividends payable | 173 | 174 | ||
| Accrued expenses | 689 | 682 | ||
| Accrued compensation and related items | 247 | 300 | ||
| Income taxes payable | 87 | 157 | ||
| Other current liabilities | 107 | 97 | ||
| Total current liabilities | 1,769 | 3,167 | ||
| Long-term debt, net of discount and issuance costs | 6,555 | 6,552 | ||
| Noncurrent deferred tax liabilities | 121 | 142 | ||
| Operating lease liabilities | 188 | 186 | ||
| Other taxes payable | 278 | 258 | ||
| Other noncurrent liabilities | 217 | 217 | ||
| Total liabilities | 9,128 | 10,522 | ||
| Commitments and contingencies (Note 15) | ||||
| Stockholders' equity: | ||||
| Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 460,750,652 and 463,808,059 shares outstanding at June 30, 2023, and December 31, 2022, respectively | 5 | 5 | ||
| Treasury stock, at cost, 41,140,591 and 38,083,184 shares of common stock at June 30, 2023 and December 31, 2022, respectively | (5,126) | (4,539) | ||
| Additional paid-in capital | 1,098 | 1,088 | ||
| Retained earnings | 9,543 | 8,668 | ||
| Accumulated other comprehensive loss | (895) | (817) | ||
| Total Zoetis Inc. equity | 4,625 | 4,405 | ||
| Noncontrolling interests | (4) | (2) | ||
| Total equity | 4,621 | 4,403 | ||
| Total liabilities and equity | $ 13,749 | $ 14,925 | ||
| ||||
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.